For initial diagnosis of BCa, cystoscopy is generally performed. However, cystoscopy can not accurately detect carcinoma insitu (CIS) and can not distinguish benign masses from malignant lesions. CT is used in two modes, CT and computed tomographic urography (CTU), both for dignosis and staging of BCa. However, they cannot differentiate T1 and T2 BCa. MRI is performed to diagnose invasive BCa and can differentiate muscle invasive bladder carcinoma (MIBC) from non-muscle invasive bladder carcinoma (NMIBC). However, CT and MRI have low sensitivity for nodal staging. For nodal staging PET/CT is preferred. PET/MRI provides better differentiation of normal and pathologic structures as compared with PET/CT. Nonetheless none of the approaches can address all issues related for the management of BCa. Novel imaging methods that target specific biomarkers, image BCa early and accurately, and stage the disease are warranted.
Keyphrases
- pet ct
- contrast enhanced
- magnetic resonance imaging
- positron emission tomography
- computed tomography
- magnetic resonance
- high resolution
- diffusion weighted imaging
- dual energy
- neoadjuvant chemotherapy
- spinal cord injury
- image quality
- lymph node
- skeletal muscle
- machine learning
- mass spectrometry
- urinary tract
- locally advanced
- fluorescence imaging
- pet imaging
- contrast enhanced ultrasound